Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis.
Expert Opin Drug Metab Toxicol
; 18(3): 235-240, 2022 Mar.
Article
em En
| MEDLINE
| ID: mdl-35485878
ABSTRACT
BACKGROUND:
PARP inhibitors (PARPi) have recently emerged as a new treatment option for several solid tumors, including metastatic castration-resistant prostate cancer (mCRPC). However, several grade 3-4 adverse events have been reported during PARPi administration, leading to limitations in treatment adherence.METHODS:
Herein, we conducted a meta-analysis aimed at analyzing the incidence rate of commonly reported grade 3-4 adverse events, dose reduction, and treatment discontinuation in mCRPC patients treated with PARPi monotherapy.RESULTS:
Incidence rate with 95% confidence intervals (CIs) of grade 3-4 toxicities, dose reduction, and treatment discontinuation were calculated. Six trials involving 752 mCRPC patients were available for the meta-analysis. According to our results, anemia was the most frequently observed grade 3-4 toxicity (24.1%), and dose reduction (26.9%) and treatment discontinuation (14.1%) were common events during PARPi treatment.CONCLUSIONS:
Clinicians should carefully consider these risks, especially taking into account that the use of PARPi in mCRPC patients is expected to rise in the near future.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias de Próstata Resistentes à Castração
/
Inibidores de Poli(ADP-Ribose) Polimerases
Tipo de estudo:
Incidence_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Systematic_reviews
Limite:
Humans
/
Male
Idioma:
En
Revista:
Expert Opin Drug Metab Toxicol
Assunto da revista:
METABOLISMO
/
TOXICOLOGIA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Itália